Notice2024-05881
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 20, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 55 (Wednesday, March 20, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 55 (Wednesday, March 20, 2024)]
[Notices]
[Pages 19856-19857]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-05881]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Peter Tung at 240-669-5483 or
<a href="/cdn-cgi/l/email-protection#95e5f0e1f0e7bbe1e0fbf2d5fbfcfdbbf2fae3"><span class="__cf_email__" data-cfemail="a0d0c5d4c5d28ed4d5cec7e0cec9c88ec7cfd6">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
Licensing information and copies of the patent applications listed
below may be obtained by communicating with the Technology Transfer and
Intellectual Property Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852 by
contacting Peter Tung at 240-669-5483 or <a href="/cdn-cgi/l/email-protection#becedbcadbcc90cacbd0d9fed0d7d690d9d1c8"><span class="__cf_email__" data-cfemail="4c3c2938293e623839222b0c222524622b233a">[email protected]</span></a>. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished patent applications related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine
Candidates and Monoclonal Antibodies
Description of Technology
This technology encompasses the development of highly advanced
malaria vaccine candidates and human monoclonal antibodies, both
centered on targeting the Merozoite Surface Protein 1 (MSP1) of the
Plasmodium falciparum malaria parasite. The innovation lies in
utilizing a novel computational design and in vitro screening process,
which has created MSP1 vaccine candidates that are significantly more
immunogenic, stable, and cost-effective than existing alternatives.
These vaccines focus on the 19 kDa carboxy-terminus fragment of MSP1.
They contain engineered amino acid changes and are displayed on self-
assembling nanoparticles to elicit a more potent immune response,
potentially offering more robust and durable protection against
malaria. Additionally, the technology includes the production of
enhanced human monoclonal antibodies with improved affinity for the
same fragment of MSP1, designed to overcome the parasite's immune
evasion tactics. These advancements hold immense promise for
significantly improving malaria prevention and treatment. They could
lead to the development of more
[[Page 19857]]
effective vaccines and therapeutic antibodies, providing a critical
solution to a significant global health challenge.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
<bullet> This MSP1-focused technology has the potential to
transform malaria treatment and prevention worldwide, offering more
effective vaccines and therapeutic antibodies for use in clinical
settings, public health programs, and potentially in regions with high
malaria prevalence.
Competitive Advantages
<bullet> This technology offers highly immunogenic and stable MSP1-
based vaccine candidates and monoclonal antibodies, with superior
efficacy, cost-effectiveness, and ease of production compared to
current alternatives.
Development Stage
Pre-Clinical
Inventors: Niraj Tolia, Ph.D., Thayne Dickey, Ph.D., Palak Patel,
Ph.D., Kazuotoyo Miura, Ph.D., Carole Long, Ph.D., all of NIAID.
Publications: Patel, Palak N et al. ``Neutralizing and interfering
human antibodies define the structural and mechanistic basis for
antigenic diversion.'' Nature communications vol. 13,1 5888. 6 Oct.
2022, doi:10.1038/s41467-022-33336-3.
Intellectual Property: HHS Reference No. E-154-2022-0-US-01, US
Provisional Application No. 63/369,909, filed on July 29, 2022; HHS
Reference No. E-154-2022-0-PC-01, PCT Application No. PCT/US2023/
070926, filed on July 25, 2023.
Licensing Contact: To license this technology, please contact Peter
Tung at 240-669-5483 or <a href="/cdn-cgi/l/email-protection#acdcc9d8c9de82d8d9c2cbecc2c5c482cbc3da"><span class="__cf_email__" data-cfemail="1060756475623e64657e77507e79783e777f66">[email protected]</span></a>, and reference E-154-2022.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Peter Tung at 240-669-5483 or
<a href="/cdn-cgi/l/email-protection#5323362736217d27263d34133d3a3b7d343c25"><span class="__cf_email__" data-cfemail="3040554455421e44455e57705e59581e575f46">[email protected]</span></a>.
Dated: March 14, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-05881 Filed 3-19-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 20, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.